| |  Online-Ressource |
|---|
| Verfasst von: | Schaaf, Axel [VerfasserIn]  |
|---|
| | Sagi, Sreedhar [VerfasserIn] |
|---|
| | Langbein, Sigrun [VerfasserIn] |
|---|
| | Trojan, Lutz [VerfasserIn] |
|---|
| | Alken, Peter [VerfasserIn] |
|---|
| | Michel, Maurice Stephan [VerfasserIn] |
|---|
| Titel: | Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides |
|---|
| Verf.angabe: | Axel Schaaf, Sreedhar Sagi, Sigrun Langbein, M.D., Lutz Trojan, M.D., Peter Alken, M.D., Maurice Stephan Michel, M.D. |
|---|
| E-Jahr: | 2004 |
|---|
| Jahr: | 20 July 2004 |
|---|
| Umfang: | 5 S. |
|---|
| Fussnoten: | Gesehen am 07.03.2022 |
|---|
| Titel Quelle: | Enthalten in: Urologic oncology |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier Science, 1995 |
|---|
| Jahr Quelle: | 2004 |
|---|
| Band/Heft Quelle: | 22(2004), 3, Seite 188-192 |
|---|
| ISSN Quelle: | 1873-2496 |
|---|
| Abstract: | Background: The aim of our study was to examine the effects of the combined application of cisplatin and bcl-2 antisense oligonucleotide on human bladder cancer cell lines to determine the possible synergistic effects in cytotoxicity and to estimate its potential value for subsequent in vivo trials. Materials and methods: Human bladder cancer cell lines (UM-UC 3, RT 112, T24/83 and HT 1197) were treated with bcl-2 antisense oligonucleotide, cisplatin, or a combination of both and incubated for 48 h under standard conditions. Cell survival was determined using a Neubauer haemocytometer or standard MTT assay. BCL-2 expression was verified using western blotting. Results: The combined treatment resulted in significant lower cell survival rates compared to individual treatment. Additionally, there was a decrease in cell survival rate with an increase in cisplatin concentration in combined treatment that was not observed in cisplatin mono treatment. Conclusions: For the combined treatment with oligonucleotides and cisplatin a synergistic effect can be strongly suggested. Therefore, further investigations and in vivo trials have to be done to determine the possible benefits for clinical applications. |
|---|
| DOI: | doi:10.1016/j.urolonc.2004.01.010 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.urolonc.2004.01.010 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S1078143904000328 |
|---|
| | DOI: https://doi.org/10.1016/j.urolonc.2004.01.010 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Antisense technology |
|---|
| | Bladder neoplasms |
|---|
| | Cytostatic agents |
|---|
| K10plus-PPN: | 1794889477 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides / Schaaf, Axel [VerfasserIn]; 20 July 2004 (Online-Ressource)
